Journal of Pharmaceutical Health Care and SciencesBackground Imbalance between gastrointestinal peptides has been implicated as a cause of chemotherapy-induced nausea and vomiting (CINV) and anorexia in cancer patients.
Ryosuke Tatsuta +9 more
doaj +1 more source
Palonostron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) during gemcitabine/cisplatin (GC) in urothelial cancer (UC) patients: A multi-institutional retrospective study in Japan. [PDF]
, 2014 362 Background: GC combination chemotherapy of is a standard regimen for advanced UC. Although this is a highly emetogenic chemotherapy, there has been no study concerning antiemetic prophylaxis for CINV during GC.
Hiroshi Kitamura +8 more
core +1 more source
Palonosetron, second generation 5-HT3 antagonist: a new perspective in CINV management [PDF]
, 2006 It is well established that the majority of cancer patients who undergo moderately or highly emetogenic cytotoxic treatment without receiving prophylactic antiemetics will experience chemotherapy-induced nausea and vomiting (CINV).
PICCALUGA, PIER PAOLO
core
A study on utilization and evaluation of antiemetics in chemotherapy-induced nausea and vomiting
Indian Journal of Medical and Paediatric Oncology, 2017 Purpose: Chemotherapy-induced nausea and vomiting (CINV) are the major adverse effects of cancer chemotherapy. The objectives of this study are to evaluate the utilization of antiemetics in CINV and to assess the emetogenicity of chemotherapy and to ...
Gayathri Baburaj +6 more
doaj +1 more source
Is Rolapitant Effective in Reducing the Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Emetogenic Chemotherapy? [PDF]
, 2017 Objective: The objective of this selective EBM review is to determine whether or not rolapitant is safe and effective in reducing the incidence of chemotherapy induced nausea and vomiting (CINV) in patients receiving emetogenic chemotherapy. Study Design:
Eberts, Brandon E
core +1 more source
BMC Health Services Research, 2012 Background 1st generation 5-hydroxytryptamine receptor antagonists (5-HT3 RAs), and palonosetron, a 2nd generation 5-HT3 RA, are indicated for the prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) associated with moderately (MEC) and ...
Lin Swu-Jane +4 more
doaj +1 more source
Olanzapine: is it enough for CINV prevention? [PDF]
Annals of Palliative Medicine, 2020 Piyawan, Tienchaiananda +2 more
openaire +2 more sources
The impact of 5HT3RA antiemetics on the incidence of chemotherapy-induced nausea and vomiting (CINV), treatment adherence, and delay of therapy in early-stage breast cancer (BC) patients treated with moderately/highly emetogenic chemotherapy (MEC/HEC). [PDF]
, 2012 75 Background: The effectiveness of 5-HT3receptor antagonists (5HTs) for the prevention of CINV is well established. Less is known about the impact of these drugs on chemotherapy adherence (AD) and preventing delayed therapy (DT).
Russell L. Knoth +4 more
core +1 more source
Indian Journal of Medical and Paediatric Oncology, 2019 Chemotherapy-induced nausea and vomiting (CINV) is a significant contributor to the treatment morbidity experienced by patients with cancer. With effective prophylactic anti-emetics given prior to administration of moderately or highly emetogenic ...
Venkatraman Radhakrishnan
doaj +1 more source
Generic Netupitant Plus Palonosetron and Dexamethasone for Prophylaxis of Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Retrospective Study [PDF]
Chemotherapy-induced nausea and vomiting (CINV) is a challenging adverse effect that is associated with deteriorating quality of life. Inhibiting neurokinin 1 and 5-hydroxytryptamine type 3 receptors involved in the major emesis pathways has ...
Mamatha Madavi +6 more
core +1 more source